CLOVER BIO-B(02197.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 954.98 million, turned profitable from a loss YoY

NewTimeSpace (newtimespace.com) News, August 26, 2026, CLOVER BIO-B(02197.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 179 thousand, decreased by 94.5% YoY; Net Profit stood at CNY 954.98 million, turned profitable from a loss YoY; Profit Attributable to Shareholders stood at CNY 954.98 million, turned profitable from a loss YoY; Basic Earnings Per Share (EPS) stood at CNY 0.75.
In terms of profitability, CLOVER BIO-B Gross Profit changed from CNY 2.48 million in the same period last year to CNY 179 thousand in the current period, decreased by CNY 2.31 million; gross profit margin changed from 76.34% in the same period last year to 100% in the current period, increased by 23.66 percentage points; net profit changed from loss of CNY 101.27 million in the same period last year to CNY 954.98 million in the current period, increased by CNY 1.06 billion; net profit margin changed from -3112.17% in the same period last year to 533506.15% in the current period, increased by 536618.32 percentage points.
In terms of earnings quality, CLOVER BIO-B Operating Profit changed from loss of CNY 101.02 million in the same period last year to CNY 955.05 million in the current period, increased by CNY 1.06 billion; Operating Profit Margin changed from -3104.55% in the same period last year to 533544.69% in the current period, increased by 536649.24 percentage points.
In terms of financial soundness, CLOVER BIO-B Debt-to-Asset Ratio changed from 387.13% in the same period last year to 431.3% in the current period, increased by 44.17 percentage points; Total Equity changed from -CNY 1.706 billion in the same period last year to -CNY 801.204 million in the current period, increased by CNY 904.92 million; Current Liabilities changed from CNY 1.76 billion in the same period last year to CNY 179.38 million in the current period, decreased by CNY 1.58 billion; Quick Ratio changed from 0.25 in the same period last year to 0.71 in the current period, increased by 0.46 percentage points.
In terms of R&D investment focus, CLOVER BIO-B R&D Expenses changed from CNY 83.25 million in the same period last year to CNY 104.84 million in the current period, increased by CNY 21.6 million; R&D to Total Revenue Ratio changed from 2558.33% in the same period last year to 58572.07% in the current period, increased by 56013.74 percentage points.
By the close of trading on August 25, 2026, CLOVER BIO-B(02197) saw a gain of 1.1% in its share price, closing at HKD 2.3. The full-day turnover stood at HKD 3.59 million, with the latest market capitalization at HKD 2.99 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.